A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

Uniting over 600 industry experts this September 22-25, the 15 th World Clinical Biomarkers & Companion Diagnostics (CDx) ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

Tive is a global leader in supply chain and logistics visibility technology. 1,000 global shippers, logistics service providers, and retailers use Tive to monitor shipment location and condition ...

1 Day. 20 Pharma Senior Speakers From GSK, Pfizer, AstraZeneca & More Explore Impactful, Value-Adding & Engaging Pharma Comms Strategies! Book 4 For The Price Of 3! Limited Discounted Places ...

New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format.

This week, it was a case of mixed fortunes for pharma companies in FDA advisory committee meetings, as experts backed one cancer drug application from Johnson & Johnson but voted against three ...

MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year.